Informations générales (source: ClinicalTrials.gov)
Prognostic Value of Circulating Endothelial Progenitor Cells in Aneurysmal Subarachnoid Hemorrhage (Evaluation de l'intérêt Pronostic Des progéniteurs endothéliaux Circulants Dans l'hémorragie Sous-arachnoïdienne Par Rupture d'anévrysme cérébral) (EVAPROPEC)
Observational
Centre Hospitalier Universitaire de Besancon (Voir sur ClinicalTrials)
mars 2013
mars 2018
29 juin 2024
Aneurysmal subarachnoid hemorrhage is a common and serious disease associated to a high
rate of mortality and morbidity. Severe definitive neurological impairment can concern up
to 30% of patients in relation with elevated intracranial pressure, hemorrhage recurrence
and symptomatic cerebral arterial vasospasm. This latter complication is defined as a
reversible reduction of cerebral artery's diameter occurring between the 4th and the 14th
day after bleeding. Physiopathology is not well understood, but could involve
endothelium, trough endothelial progenitor cells (EPC). Circulating EPC are bone
marrow-derived cells with capacity of vasculogenesis and angiogenesis. EPC have been
recognized playing a beneficial role in cardiovascular disease and ischemic stroke. EPC
have never been studied in aneurysmal subarachnoid hemorrhage.
The primary objective of this study is to compare the number of circulating endothelial
progenitor cells between patients with a good neurological outcome (defined as a glasgow
outcome scale = 1 or 2) and patients with a poor neurological outcome (glasgow outcome
scale = 3, 4 or 5).
Briefly, the number of circulating EPC will be measured at admission, and at day 3, 6,
10, 14, 21 in each consecutive patient suffering aneurysmal subarachnoid hemorrhage and
hospitalized in Teaching Hospital of Besançon (France). The neurological outcome will be
measured one year after subarachnoid hemorrhage.
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CHRU de Besançon - 25000 - Besançon - France | Contact (sur clinicalTrials) | ||||
Critères
Tous
Inclusion Criteria:
- recent(< 24 h) aneurysmal subarachnoid hemorrhage
- written informed consent obtained from the patient or from close relatives
- recent(< 24 h) aneurysmal subarachnoid hemorrhage
- written informed consent obtained from the patient or from close relatives
- refusal to participate
- Non-aneurysmal subarachnoid hemorrhage
- aneurysmal subarachnoid hemorrhage with estimated date of bleeding > 24 h
- Chronic heart failure
- Chronic medication able to modify the plasmatic level of BNP
- Pregnancy